3-formylindole-1-butanoic acid | 887405-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-formylindole-1-butanoic acid
• 英文别名: 4-(3-formyl-1H-indol-1-yl)butanoic acid；4-(3-formylindol-1-yl)butanoic acid
• CAS: 887405-75-6
• 化学式: C₁₃H₁₃NO₃
• mdl: MFCD07437726
• 分子量: 231.251
• InChiKey: VHQDVTDPTCDCJX-UHFFFAOYSA-N

物化性质

• 沸点：
  483.9±25.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-formylindole-1-butanoic acid 在 camphor-10-sulfonic acid 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 6.67h， 生成 2,3-Dihydro-1H-pyrrolo<1,2-a>indole-9-carboxaldehyde 、 methyl 11-formyl-7,8-dihydro-6H-azepino[1,2-a]indole-10-carboxylate
  参考文献：
  名称：

  通过Barton酯进行分子间加成和乙烯基自由基取代到吲哚上的串联反应

  摘要：

  一锅式无引发剂的Barton酯分解反应，将自由基串联添加到丙炔酸烷基酯或苯乙炔上，并用芳香族取代所得的乙烯基，可以方便地获得新的9-取代的6,7-二氢吡啶并[1,2- a ]吲哚。丙基自由基环化在形成扩展的7,8-二氢-6 H-氮杂环庚烷[1,2- a ]吲哚体系时竞争。当使用未取代的吲哚-1-链烷酸前体时，将2-硫代吡啶基S-自由基结合到芳族加合物中。取代产物的X射线晶体学分析可以确定将自由基加成到反应性较低的内部炔烃上的选择性。

  DOI：

  10.1021/jo5008543
• 作为产物：
  描述：

  ethyl 4-(3-formylindol-1-yl)butyrate 在 sodium hydroxide 作用下， 以 水 为溶剂， 以60 %的产率得到3-formylindole-1-butanoic acid
  参考文献：
  名称：

  开发用于活细胞中 RNA 动力学成像的高选择性和高灵敏度荧光探针

  摘要：

  RNA 成像对于了解其复杂的时空动力学和细胞功能非常重要。已投入大量精力开发用于 RNA 成像的小分子荧光探针。然而，大多数报道的研究主要集中在提高 RNA 探针的光稳定性、渗透性、长发射波长以及与活细胞成像的兼容性。对这类探针的选择性和检测限关注较少。高选择性和灵敏的 RNA 探针仍然很少可用。在这项研究中，设计和合成了一组新的苯乙烯基探针，目的是提高检测限并保持先导探针QUID-1对 RNA 的选择性。在这些新合成的化合物中，QUID-2是最有希望的候选人。QUID-2对 RNA的检测限 (LOD) 值在溶液中高达 1.8 ng/mL。与QUID-1相比，该属性得到了显着改善。进一步的光谱学和细胞成像研究表明，QUID-2在高选择性和灵敏的 RNA 成像方面优于市售的 RNA 染色探针 SYTO RNASelect。此外，QUID-2表现出优异的光稳定性和低细胞毒性。使用QUID-2，在活细胞中揭示了

  DOI：

  10.3390/molecules27206927

文献信息

• Organic compounds
  申请人：Novartis AG

  公开号：EP2177518A1

  公开（公告）日：2010-04-21

  3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I, wherein the symbols have the meanings defined in the specification.

  3,4-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖于肾素活性的疾病的药物制剂；公开了该类化合物在治疗依赖肾素活性的疾病中的用途；包含3,4-取代的哌啶化合物的药物制剂，和/或包括施用3,4-取代的哌啶化合物的治疗方法，3,4-取代的哌啶化合物的制造方法，以及新型中间体及其合成的部分步骤。3,4-二取代哌啶化合物具有式 I、 其中符号具有本说明书中定义的含义。
• SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS
  申请人：Novartis AG

  公开号：EP1833816B1

  公开（公告）日：2009-11-11
• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090312304A1

  公开（公告）日：2009-12-17

  3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I,
• Organic Compounds
  申请人：BREITENSTEIN Werner

  公开号：US20110263560A1

  公开（公告）日：2011-10-27

  3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.
• US8084450B2
  申请人：——

  公开号：US8084450B2

  公开（公告）日：2011-12-27